No Data
No Data
Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) First-Quarter Report
The quarterly results for Zevra Therapeutics, Inc. (NASDAQ:ZVRA) were released last week, making it a good time to revisit its performance. Revenues of US$3.4m came in 8.9% below estimates, but
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), ALX Oncology Holdings (ALXO) and Quoin Pharmaceuticals (QNRX)
Analysts Are Bullish on Top Healthcare Stocks: Regulus (RGLS), Zevra Therapeutics (ZVRA)
10-Q: Quarterly report
Strong Buy Rating for Zevra Therapeutics Based on Solid Financials and Promising Drug Pipeline
Zevra Therapeutics to Participate at Upcoming Investor Events
CELEBRATION, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief
No Data